Are you Dr. Polizzotto?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Bldg 10 RM 6n110
National Institutes of Health 9000 Rockville Pike
Bethesda, MD 20892Phone+1 301-402-1541Fax+1 301-480-5955
Clinical Trials
- Body Composition Sub-study of the D2EFT Trial Start of enrollment: 2019 Dec 05
- Inflammation and Co-Infections in D²EFT Start of enrollment: 2021 Feb 01
Publications & Presentations
PubMed
- 77 citationsViral, immunologic, and clinical features of primary effusion lymphoma.Kathryn Lurain, Mark N. Polizzotto, Karen Aleman, Manisha Bhutani, Kathleen M. Wyvill
Blood. 2019-04-18 - 21 citationsSafety, activity, and long-term outcomes of pomalidomide in the treatment of Kaposi sarcoma among individuals with or without HIV infection.Ramya Ramaswami, Mark N. Polizzotto, Kathryn Lurain, Kathleen M. Wyvill, Anaida Widell
Clinical Cancer Research. 2021-12-03 - 54 citationsRecent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.Thomas S. Uldrick, Mark N. Polizzotto, Robert Yarchoan
Current Opinion in Oncology. 2012-09-01
Press Mentions
COVID Booster: Mixing and Matching Boosters, Delayed Surgery, and Testing Recalcitrant ChildrenJanuary 29th, 2022- IV Hyperimmune Immunoglobulin No Help in Severe COVIDJanuary 28th, 2022
- International Trial Uncovers Crucial Gaps in Our Understanding of Influenza TherapiesNovember 27th, 2020
- Join now to see all
